|
| ID |
DDInter648 |
| Drug Type |
small molecule |
| Molecular Formula |
C31H34F2N6O2 |
| Molecular Weight |
560.649
|
| Description |
Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor.[L8081] It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors.[L8207] Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets.[A183929]
|
| ATC Classification |
L01XE56
|
| IUPAC Name |
N-{5-[(3,5-Difluorophenyl)Methyl]-1H-Indazol-3-Yl}-4-(4-Methylpiperazin-1-Yl)-2-[(Oxan-4-Yl)Amino]Benzamide |
| InChI |
Inchi=1S/C31H34F2N6O2/C1-38-8-10-39(11-9-38)25-3-4-26(29(19-25)34-24-6-12-41-13-7-24)31(40)35-30-27-17-20(2-5-28(27)36-37-30)14-21-15-22(32)18-23(33)16-21/H2-5,15-19,24,34H,6-14H2,1H3,(H2,35,36,37,40) |
| InChI Key |
HAYYBYPASCDWEQ-UHFFFAOYSA-N |
| Canonical SMILES |
CN1CCN(CC1)C1=CC=C(C(=O)NC2=NNC3=CC=C(CC4=CC(F)=CC(F)=C4)C=C23)C(NC2CCOCC2)=C1 |
| Useful Links |
DrugBank
ChEMBL
PubChem
|